Standard BioTools Inc.

NASDAQ:LAB

Medical - Devices

Healthcare
$0.57 +3.38%

+$0.03 today

Market cap
$225.03M
Beta
1.38
P/E (TTM)
-3.5
EPS (TTM)
-$0.24
52W Low $0.79High $1.72

Volume 0.70M

Average 2.91M

LAB Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

Standard BioTools Inc.NASDAQ: LAB

Total Equity · Q1 FY2026 · quarter ended Mar 2026

Total equity rises 23.4% from a year ago

Total equity stood at $561.12M at the end of Q1 FY2026, up 23.4% from a year earlier and up 32.2% from the prior quarter.

Context

  • Total equity amounted to 87.8% of total assets at the end of Q1 FY2026, up 9.4 pp from a year earlier.
  • Total equity increased in 1 of the last 3 fiscal years.

What to watch

Whether total equity keeps rising in the next quarterly balance sheet after a +23.4% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$561.12M+32.2% QoQ
Last fiscal yearDec 2025
$424.29M-10.1% YoY
Year agoMar 2025
$454.6M+23.4% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+23.4%——
1 year-10.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Total Equity history

USD · from the balance sheet

Latest · FY2025
424.29M USD
Year-over-year change
-10.1%
4-year CAGR
+45.5%

Total Equity vs competitors

How LAB compares with its peers on the latest reported figures

  • Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +23.4% is the 2nd highest of 11, against a peer median of -13.6%.
  • Total equity amounts to 87.8% of total assets for LAB, versus a peer median of 70.2%.
LAB Competitors
Total Equity for LAB and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
SYSo-Young International Inc.Mar 2026CN¥1.6B CNY-15.7%-13.8%60.4%
AVNSAvanos Medical, Inc.Mar 2026$782.1M USD-6.8%-15.5%74.5%
LABStandard BioTools Inc.Mar 2026$561.12M USD+23.4%—87.8%
VREXVarex Imaging CorporationApr 2026$488.1M USD-13.4%-3.8%44.8%
CGEMCullinan Therapeutics, Inc.Mar 2026$366.17M USD-33.6%-8.6%90.9%
KIDSOrthoPediatrics Corp.Mar 2026$338.71M USD-2.4%-2.9%67.4%
CTKBCytek Biosciences, Inc.Mar 2026$327.64M USD-13.7%-7.1%73.0%
BVSBioventus Inc.Mar 2026$234.27M USD+26.3%-17.9%36.0%
CBLLCeriBell, Inc.Mar 2026$140.81M USD-22.2%—79.1%
TMCITreace Medical Concepts, Inc.Mar 2026$77.19M USD-26.7%+13.0%41.9%
ADCTADC Therapeutics S.A.Mar 2026-$216.38M USD+9.2%—74.2%
Peer median (excluding LAB) —-13.6%-7.8%70.2%

Competitors are the stored peer set for LAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents28.45M81.31M51.7M166.73M118.21M
Short-term Investments084.48M63.19M126.15M69.36M
Net Receivables18.32M17.28M19.66M33.61M13.43M
Inventory20.83M21.47M20.53M40.74M19.98M
Other Current Assets16K4.28M3.13M8.66M233.28M
Total Current Assets72.07M208.82M158.22M375.88M454.26M
Property, Plant & Equipment (Net)65.15M59.54M54.85M71.38M46.01M
Goodwill106.38M106.25M106.32M111.3M0
Intangible Assets27.93M12.6M1.4M28.95M0
Long-term Investments1M00025.7M
Tax Assets(1M)00038.63M
Other Non-current Assets3.69M3.11M2.29M24.83M3.15M
Total Non-current Assets203.15M181.5M164.85M236.46M113.49M
Total Assets275.21M390.31M323.07M612.34M567.75M
Account Payables10.6M7.91M9.24M12.28M5.41M
Short-term Debt6.84M2.08M59.53M05.49M
Tax Payables1.41M1.17M825K1.58M0
Deferred Revenue15.48M14.44M16.74M18.59M38.95M
Other Current Liabilities8.67M3.97M12.05M14.71M58.46M
Total Current Liabilities49.57M43.44M109.33M65.89M108.31M
Long-term Debt64.21M62.81M3.98M299K299K
Deferred Tax Liabilities4.33M1.06M841K1.08M810K
Deferred Revenue (Non-current)24.08M18.18M14.28M39.92M7.79M
Other Non-current Liabilities882K312.21M312.32M6.96M1.21M
Total Non-current Liabilities131.05M428.33M361.79M74.73M35.15M
Total Liabilities180.62M471.78M471.12M140.62M143.46M
Common Stock77K80K83K396K404K
Retained Earnings(736M)(926.1M)(1B)(1.19B)(1.26B)
Accumulated OCI(907K)(1.9M)(2.22M)1.23M(1.49M)
Other Stockholders Equity00000
Minority Interest00000
Total Equity94.6M(81.47M)(148.05M)471.72M424.29M
Total Debt111.65M102.66M98.21M33M30.83M
Net Debt83.2M21.35M46.51M(133.73M)(87.39M)

Standard BioTools Inc.

NASDAQ:LAB

Intrinsic Alpha fair value

Locked

Current Price

$0.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.